Role of MCP-1 as an inflammatory biomarker in nephropathy

• DOI: 10.3389/fimmu.2023.1303076
• Publication Date: 2024-01-04T04:47:28Z
• Authors: Yanlong Liu; Ke Xu; Yuhua Xiang; Boyan Ma; Hailong Li; Yuan Li; Yue Shi; Shuju Li; Yan Bai
• Keywords: Glomerulopathy

The Monocyte chemoattractant protein-1 (MCP-1), also referred to as chemokine ligand 2 (CCL2), belongs the extensive family and serves a crucial mediator of innate immunity tissue inflammation. It has notable impact on inflammatory conditions affecting kidneys. Upon binding its receptor, MCP-1 can induce lymphocytes NK cells’ homing, migration, activation, differentiation, development while promoting monocytes’ macrophages’ infiltration, thereby facilitating kidney disease-related As biomarker for disease, made advancements in primary diseases such crescentic glomerulonephritis, chronic glomerulopathy, idiopathic proteinuria acute injury; secondary like diabetic nephropathy lupus nephritis; hereditary including autosomal dominant polycystic disease sickle cell disease. not only predicts occurrence, progression, prognosis but is closely associated with severity stage nephropathy. When renal stimulated or experiences significant damage, expression increases, demonstrating direct correlation injury.